MBRX

+ Watchlist + Portfolio

Moleculin Biotech, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.57
52-Week Range: $0.16 – $15.75
Market Cap: $11.50M
P/E (TTM): 0.04
EPS (TTM): 14.59
Dividend Yield: —

Advanced Metrics

Price/Book: 0.21
PEG Ratio: —
Return on Equity: -1395.70%
Return on Assets: -84.56%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.94
Debt/Equity: 0.01
Total Debt: $147.00K
Free Cash Flow: $-15.59M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $4.03M

MBRX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$18.97M	$19.49M	$17.73M	$15.89M
Selling, General & Admin	$11.54M	$10.02M	$8.79M	$9.12M
Operating Expenses	$30.64M	$29.63M	$26.64M	$25.10M
Operating Income	-$30.64M	-$29.63M	-$26.64M	-$25.10M
EBITDA	-$30.51M	-$29.50M	-$26.52M	-$25.01M
Pretax Income	-$29.02M	-$29.77M	-$26.05M	-$33.56M
Net Income	-$29.02M	-$29.77M	-$26.05M	-$33.56M
Diluted EPS	-378.75	-376.75	-189.14	-28.42
Diluted Shares	76278	79024	137720	1.18M

MBRX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$43.15M	$23.55M	$4.28M	$8.88M
Receivables	$22.00K	$99.00K	$20.00K	$7.00K
Current Assets	$45.60M	$26.27M	$5.19M	$9.69M
Total Assets	$57.42M	$38.22M	$16.93M	$22.13M
Current Liabilities	$4.82M	$6.82M	$5.36M	$6.85M
Total Debt	$451.00K	$574.00K	$478.00K	$359.00K
Total Liabilities	$5.23M	$12.14M	$5.72M	$7.12M
Retained Earnings	-$101.83M	-$131.60M	-$172.44M	-$206.00M
Shareholders' Equity	$52.19M	$26.07M	$11.21M	$15.01M
Working Capital	$40.78M	$19.46M	-$165.00K	$2.83M

MBRX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$27.64M	-$23.59M	-$23.86M	-$22.73M
Capital Expenditure	-$67.00K	-$124.00K	-$13.00K	—
Free Cash Flow	-$27.71M	-$23.71M	-$23.88M	-$22.73M
Depreciation & Amortisation	$130.00K	$127.00K	$126.00K	$90.00K
Stock-Based Compensation	$2.27M	$1.98M	$1.73M	$1.66M
Investing Cash Flow	-$67.00K	-$124.00K	-$13.00K	$0.00
Financing Cash Flow	-$23.00K	$4.14M	$4.63M	$27.28M
Net Change in Cash	-$27.73M	-$19.57M	-$19.24M	$4.55M

MBRX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.44M	$3.60M	$3.74M	$5.12M	$5.38M
Selling, General & Admin	$2.48M	$2.09M	$2.15M	$2.41M	$2.49M
Operating Expenses	$5.94M	$5.72M	$5.91M	$7.53M	$7.87M
Operating Income	-$5.94M	-$5.72M	-$5.91M	-$7.53M	-$7.87M
EBITDA	-$5.91M	-$5.69M	-$5.88M	-$7.52M	-$7.87M
Pretax Income	-$5.90M	-$7.64M	-$25.40M	$15.55M	-$12.85M
Net Income	-$5.90M	-$7.64M	-$25.40M	$15.55M	-$12.85M
Diluted EPS	-15.80	-12.25	-17.00	—	-3.54
Diluted Shares	373751	621056	1.49M	—	4.12M

MBRX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$7.72M	$7.56M	$6.70M	$8.88M	$10.32M
Receivables	$6.00K	$5.00K	$6.00K	$7.00K	$9.00K
Current Assets	$9.34M	$9.08M	$7.88M	$9.69M	$10.96M
Total Assets	$21.01M	$21.59M	$20.35M	$22.13M	$23.36M
Current Liabilities	$6.90M	$7.91M	$5.68M	$6.85M	$7.96M
Total Debt	$450.00K	$420.00K	$390.00K	$359.00K	$326.00K
Total Liabilities	$20.97M	$28.76M	$47.27M	$7.12M	$8.18M
Retained Earnings	-$159.80M	-$167.44M	-$221.56M	-$206.00M	-$218.85M
Shareholders' Equity	$42.00K	-$7.17M	-$26.92M	$15.01M	$15.18M
Working Capital	$2.44M	$1.16M	$2.20M	$2.83M	$3.00M

MBRX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$4.56M	-$5.58M	-$7.22M	-$5.37M	-$6.11M
Free Cash Flow	-$4.56M	-$5.58M	-$7.22M	-$5.37M	-$6.11M
Depreciation & Amortisation	$31.00K	$28.00K	$22.00K	$9.00K	$8.00K
Stock-Based Compensation	$485.00K	$417.00K	$303.00K	$459.00K	$380.00K
Investing Cash Flow	$0.00	$0.00	$0.00	$0.00	$0.00
Financing Cash Flow	$8.00M	$5.42M	$6.38M	$7.49M	$7.61M
Net Change in Cash	$3.44M	-$159.00K	-$848.00K	$2.12M	$1.50M

Market Snapshot

About

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company developing oncology drug candidates for resistant and difficult-to-treat tumors. The company focuses on novel anti-tumor agents targeting highly refractory cancers, including glioblastoma, pancreatic cancer, and acute myeloid leukemia. Their pipeline includes small molecules designed to disrupt multiple tumor defense mechanisms simultaneously.